Question explored with the scientific record
Conversation so far
- 1 Bromantane
- 2 What do we know about long-term safety and side effects in people?
Answered on this page ↓
What do we know about long-term safety and side effects in people?
The short version: the retrieved evidence contains no studies on bromantane's long-term safety or side effects in humans.
The evidence block returned studies on other drugs entirely: antiepileptics, antimalarials, anticoagulants, and GLP-1 agonists [1, 2]. None of them test or mention bromantane. The 2007 rat study on ladasten (a bromantane analog) shows a dopaminergic mechanism and synaptic plasticity effects, but it is an animal experiment with no human safety data [1].
What this means for you: the retrieval simply did not find any human long-term safety studies on bromantane. That is a fact about this search, not a finding that such studies do not exist. Outside this retrieval, the broader literature on bromantane is known to be thin, mostly Russian-language, and short-term. No retrieved record provides a rate of adverse events, a follow-up duration, or a comparison against untreated controls in people.
My call: the evidence is not clear. No long-term human safety data for bromantane was retrieved. Confidence: low.
Sources used 2
-
The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats
The study shows that the adamantane derivative ladasten modulates dopaminergic synthesis in rat brain regions and, when applied to hippocampal slices, reinforces short-term potentiation into long-term potentiation via dopamine receptor- and protein synthesis-dependent mechanisms…
DOI: 10.1016/j.neuropharm.2007.07.001 -
Neuro-psychiatric effects of antimalarials
This prospective cohort study investigates the neuro-psychiatric adverse effects of antimalarial drugs, particularly mefloquine, in travelers, revealing a higher incidence of insomnia and other psychiatric symptoms compared to non-users and users of proguanil.
DOI: 10.1007/s002280050240